Orthocell takes off

SHARES in biotech Orthocell have soared after a leading scientific publication published data on Orthocell’s collaborative research on regenerating cartilage. Yesterday, Orthocell was up 8.5c, or 18.28 per cent, at 55c. Orthocell is developing cell- based therapies that aim to regenerate damaged tendon and cartilage tissue. Its projects include the fabrication of human tendon outside of the body for full tendon replacement. Perthbased Orthocell says publication of the research data further validates its products derived from cells cultivated in a “cell factory”.